Skip to content
2000
Volume 5, Issue 1
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882
file format pdf download PDF
side by side viewer icon HTML

Abstract

Pulmonary hypertension (PH) due to left heart disease (PH-LHD) is the most common type of PH and is observed in patients with underlying left heart disease conditions, including valvular heart disease, heart failure (HF) with preserved ejection fraction (HFpEF), HF with reduced ejection fraction (HFrEF), cardiomyopathies, and arrhythmic diseases. Group 2 PH is postcapillary PH categorised into 2 components as isolated postcapillary PH (IpcPH) and combined precapillary and postcapillary PH (CpcPH), based on the value of pulmonary vascular resistance (PVR).

PH-LHD diagnosis is a three-step process and includes identification of clinical phenotype, determination of pre-test probability for invasive evaluation, and haemodynamic assessments. Management of PH-LHD primarily encompasses optimisation of treatment of underlying conditions, such as hypertension, obesity and diabetes mellitus, and treatment of PH-LHD with targeted PAH-specific drugs, like phosphodiesterase type 5 inhibitors (PDE5i) and sildenafil. In patients with PH-LHD, the use of PAH-specific drugs can lead to pulmonary oedema and clinical deterioration.

The article aimed to provide updated information on diagnosis and emerging treatment options for PH-LHD. Although the emerging alternative treatment options are not approved, the randomised studies discussed provide insight into the management and thus demand future clinical trials to establish the safety and efficacy of novel molecules and combination therapies.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/0102506882333546250115060157
2024-01-01
2025-10-31

  • From This Site

    /content/journals/nemj/10.2174/0102506882333546250115060157
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/nemj/5/1/NEMJ-5-E02506882333546.html?itemId=/content/journals/nemj/10.2174/0102506882333546250115060157&mimeType=html&fmt=ahah

References

  1. VachiéryJ.L. AdirY. BarberàJ.A. ChampionH. CoghlanJ.G. CottinV. De MarcoT. GalièN. GhioS. GibbsJ.S.R. MartinezF. SemigranM. SimonneauG. WellsA. SeegerW. Pulmonary hypertension due to left heart diseases.J. Am. Coll. Cardiol.20136225Suppl.D100D10810.1016/j.jacc.2013.10.03324355634
     [Google Scholar]
  2. JangA.Y. ParkS.J. ChungW.J. Pulmonary hypertension in heart failure.Int. J. Heart Fail.20213314715910.36628/ijhf.2020.005336262642
     [Google Scholar]
  3. AtesK DemirM Importance of epicardial adipose tissue as a predictor of heart failure with preserved ejection fraction.Rev. Assoc. Med. Bras.20226891178118410.1590/1806‑9282.20220069
     [Google Scholar]
  4. SimonneauG. MontaniD. CelermajerD.S. DentonC.P. GatzoulisM.A. KrowkaM. WilliamsP.G. SouzaR. Haemodynamic definitions and updated clinical classification of pulmonary hypertension.Eur. Respir. J.2019531180191310.1183/13993003.01913‑201830545968
     [Google Scholar]
  5. VachiéryJ.L. TedfordR.J. RosenkranzS. PalazziniM. LangI. GuazziM. CoghlanG. ChazovaI. De MarcoT. Pulmonary hypertension due to left heart disease.Eur. Respir. J.2019531180189710.1183/13993003.01897‑201830545974
     [Google Scholar]
  6. HumbertM. KovacsG. HoeperM.M. BadagliaccaR. BergerR.M.F. BridaM. CarlsenJ. CoatsA.J.S. Escribano-SubiasP. FerrariP. FerreiraD.S. GhofraniH.A. GiannakoulasG. KielyD.G. MayerE. MeszarosG. NagavciB. OlssonK.M. Pepke-ZabaJ. QuintJ.K. RådegranG. SimonneauG. SitbonO. ToniaT. ToshnerM. VachieryJ.L. Vonk NoordegraafA. DelcroixM. RosenkranzS. SchwerzmannM. Dinh-XuanA.T. BushA. AbdelhamidM. AboyansV. ArbustiniE. AsteggianoR. BarberàJ.A. BeghettiM. ČelutkienėJ. CikesM. CondliffeR. de ManF. FalkV. FauchierL. GaineS. GaliéN. Gin-SingW. GrantonJ. GrünigE. HassounP.M. HellemonsM. JaarsmaT. KjellströmB. KlokF.A. KonradiA. KoskinasK.C. KotechaD. LangI. LewisB.S. LinhartA. LipG.Y.H. LøchenM.L. MathioudakisA.G. MindhamR. MoledinaS. NaeijeR. NielsenJ.C. OlschewskiH. OpitzI. PetersenS.E. PrescottE. RakishevaA. ReisA. RistićA.D. RocheN. RodriguesR. Selton-SutyC. SouzaR. SwiftA.J. TouyzR.M. UlrichS. WilkinsM.R. WortS.J. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.Eur. Heart J.202243383618373110.1093/eurheartj/ehac23736017548
     [Google Scholar]
  7. KlapholzM. MaurerM. LoweA.M. MessineoF. MeisnerJ.S. MitchellJ. KalmanJ. PhillipsR.A. SteingartR. BrownE.J.Jr BerkowitzR. MoskowitzR. SoniA. ManciniD. BijouR. SehhatK. VarshneyaN. KukinM. KatzS.D. SleeperL.A. Le JemtelT.H. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction.J. Am. Coll. Cardiol.20044381432143810.1016/j.jacc.2003.11.04015093880
     [Google Scholar]
  8. SchwartzenbergS. RedfieldM.M. FromA.M. SorajjaP. NishimuraR.A. BorlaugB.A. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy.J. Am. Coll. Cardiol.201259544245110.1016/j.jacc.2011.09.06222281246
     [Google Scholar]
  9. LeungC.C. MoondraV. CatherwoodE. AndrusB.W. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction.Am. J. Cardiol.2010106228428610.1016/j.amjcard.2010.02.03920599017
     [Google Scholar]
  10. GuazziM. Pulmonary hypertension in heart failure preserved ejection fraction: prevalence, pathophysiology, and clinical perspectives.Circ. Heart Fail.20147236737710.1161/CIRCHEARTFAILURE.113.00082324643889
     [Google Scholar]
  11. ShahS.J. Matchmaking for the optimization of clinical trials of heart failure with preserved ejection fraction: no laughing matter.J. Am. Coll. Cardiol.201362151339134210.1016/j.jacc.2013.07.01023916923
     [Google Scholar]
  12. PieskeB. TschöpeC. de BoerR.A. FraserA.G. AnkerS.D. DonalE. EdelmannF. FuM. GuazziM. LamC.S.P. LancellottiP. MelenovskyV. MorrisD.A. NagelE. Pieske-KraigherE. PonikowskiP. SolomonS.D. VasanR.S. RuttenF.H. VoorsA.A. RuschitzkaF. PaulusW.J. SeferovicP. FilippatosG. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).Eur. Heart J.201940403297331710.1093/eurheartj/ehz64131504452
     [Google Scholar]
  13. ReddyY.N.V. CarterR.E. ObokataM. RedfieldM.M. BorlaugB.A. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction.Circulation2018138986187010.1161/CIRCULATIONAHA.118.03464629792299
     [Google Scholar]
  14. KosiborodM.N. AbildstrømS.Z. BorlaugB.A. ButlerJ. RasmussenS. DaviesM. HovinghG.K. KitzmanD.W. LindegaardM.L. MøllerD.V. ShahS.J. TreppendahlM.B. VermaS. AbhayaratnaW. AhmedF.Z. ChopraV. EzekowitzJ. FuM. ItoH. LelonekM. MelenovskyV. MerkelyB. NúñezJ. PernaE. SchouM. SenniM. SharmaK. Van der MeerP. von LewinskiD. WolfD. PetrieM.C. Semaglutide in patients with heart failure with preserved ejection fraction and obesity.N. Engl. J. Med.2023389121069108410.1056/NEJMoa230696337622681
     [Google Scholar]
  15. KashourT. AlhabeebW. IdreesM.M. GhioS. Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: pulmonary hypertension due to left heart disease.Ann. Thorac. Med.201495Suppl. 14710.4103/1817‑1737.13402625076997
     [Google Scholar]
  16. BermejoJ. YottiR. García-OrtaR. Sánchez-FernándezP.L. CastañoM. Segovia-CuberoJ. Escribano-SubíasP. San RománJ.A. BorrásX. Alonso-GómezA. BotasJ. Crespo-LeiroM.G. VelascoS. Bayés-GenísA. LópezA. Muñoz-AguileraR. de TeresaE. González-JuanateyJ.R. EvangelistaA. MombielaT. González-MansillaA. ElízagaJ. Martín-MoreirasJ. González-SantosJ.M. Moreno-EscobarE. Fernández-AvilésF. BermejoJ. YottiR. MombielaT. Gónzález-MansillaA. ElízagaJ. García-RoblesJ.A. Pérez-DavidE. Pérez del VillarC. SanzR. Gutierrez-IbanesE. VázquezM.E. MurA. BenitoY. Martínez-LegazpiP. BarrioA. VázquezA. García-OrtaR. UribeI. GonzálezM. Luis SánchezP. González-SantosJ.M. Martín-MoreirasJ. ArribasA. Clemente LorenzoM.M. Diego NietoA. CastañoM. Pérez de PradoA. AlonsoD. Segovia-CuberoJ. Gómez-BuenoM. Sayago SilvaI. Ángel CaveroM. Escribano-SubiasP. DomínguezL. Tello de MenesesR. Ruiz CanoM.J. Jiménez López-GuarchC. San RománJ.A. MotaP. BorrásX. Amorós GalitóC. Alonso-GómezA. Belló MoraM.C. Mesa RubioD. BotasJ. CampuzanoR. Crespo-LeiroM.G. MarzoaR. CuencaJ. VelascoS. MuñozR. SuberviolaV. Beltrán HerreraC. MoraL. Mar SarriónM. VaquerizaD. Bayes-GenísA. FerrerE. González-JuanateyJ.R. CidB. MonzonísA.M. LópezA. Arizón de PradoJ.M. SantistebanM. Mesa RubioD. EvangelistaA. García-DoradoD. de TeresaE. Jiménez-NavarroM. Carrasco ChinchillaF. Moreno-EscobarE. AlonsoJ. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.Eur. Heart J.201839151255126410.1093/eurheartj/ehx70029281101
     [Google Scholar]
  17. BondermanD. GhioS. FelixS.B. GhofraniH.A. MichelakisE. MitrovicV. OudizR.J. BoatengF. ScaliseA.V. RoessigL. SemigranM.J. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.Circulation2013128550251110.1161/CIRCULATIONAHA.113.00145823775260
     [Google Scholar]
  18. SolomonS.D. McMurrayJ.J.V. AnandI.S. GeJ. LamC.S.P. MaggioniA.P. MartinezF. PackerM. PfefferM.A. PieskeB. RedfieldM.M. RouleauJ.L. van VeldhuisenD.J. ZannadF. ZileM.R. DesaiA.S. ClaggettB. JhundP.S. BoytsovS.A. Comin-ColetJ. ClelandJ. DüngenH.D. GoncalvesovaE. KatovaT. Kerr SaraivaJ.F. LelonekM. MerkelyB. SenniM. ShahS.J. ZhouJ. RizkalaA.R. GongJ. ShiV.C. LefkowitzM.P. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction.N. Engl. J. Med.2019381171609162010.1056/NEJMoa190865531475794
     [Google Scholar]
  19. AnkerS.D. ButlerJ. FilippatosG.S. JamalW. SalsaliA. SchneeJ. KimuraK. ZellerC. GeorgeJ. BrueckmannM. ZannadF. PackerM. Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial.Eur. J. Heart Fail.201921101279128710.1002/ejhf.159631523904
     [Google Scholar]
  20. BhattD.L. SzarekM. StegP.G. CannonC.P. LeiterL.A. McGuireD.K. LewisJ.B. RiddleM.C. VoorsA.A. MetraM. LundL.H. KomajdaM. TestaniJ.M. WilcoxC.S. PonikowskiP. LopesR.D. VermaS. LapuertaP. PittB. Sotagliflozin in patients with diabetes and recent worsening heart failure.N. Engl. J. Med.2021384211712810.1056/NEJMoa203018333200892
     [Google Scholar]
  21. BhattD.L. SzarekM. PittB. CannonC.P. LeiterL.A. McGuireD.K. LewisJ.B. RiddleM.C. InzucchiS.E. KosiborodM.N. CherneyD.Z.I. DwyerJ.P. SciricaB.M. BaileyC.J. DíazR. RayK.K. UdellJ.A. LopesR.D. LapuertaP. StegP.G. Sotagliflozin in patients with diabetes and chronic kidney disease.N. Engl. J. Med.2021384212913910.1056/NEJMoa203018633200891
     [Google Scholar]
  22. SolomonS.D. McMurrayJ.J.V. ClaggettB. de BoerR.A. DeMetsD. HernandezA.F. InzucchiS.E. KosiborodM.N. LamC.S.P. MartinezF. ShahS.J. DesaiA.S. JhundP.S. BelohlavekJ. ChiangC.E. BorleffsC.J.W. Comin-ColetJ. DobreanuD. DrozdzJ. FangJ.C. Alcocer-GambaM.A. Al HabeebW. HanY. Cabrera HonorioJ.W. JanssensS.P. KatovaT. KitakazeM. MerkelyB. O’MearaE. SaraivaJ.F.K. TereshchenkoS.N. ThiererJ. VaduganathanM. VardenyO. VermaS. PhamV.N. WilderängU. ZaozerskaN. BachusE. LindholmD. PeterssonM. LangkildeA.M. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.N. Engl. J. Med.2022387121089109810.1056/NEJMoa220628636027570
     [Google Scholar]
  23. KagerY. OkiT. IuchiA. TabataT. ItoS. Relationship between pulmonary capillary wedge V wave and transmitral and pulmonary venous flow velocity patterns in various heart diseases.J. Card. Fail.19962321522210.1016/S1071‑9164(96)80044‑38891860
     [Google Scholar]
  24. McLaughlinD.P. StoufferG.A. Chapter 5 - The Atrial Waveform.Cardiovascular Hemodynamics for the Clinician2nd Ed. StoufferG.A. KleinJ.L. McLaughlinD.P. Hoboken, New Jersey, U.S.John Wiley & Sons Ltd2016137110.1002/9781119066491.ch5
     [Google Scholar]
/content/journals/nemj/10.2174/0102506882333546250115060157
Loading
Diagnosis and Management of Group 2 Pulmonary Hypertension Due to Left Heart Disease in the UAE
NEW Emirates Medical J 5, e02506882333546 (2024); https://doi.org/10.2174/0102506882333546250115060157
/content/journals/nemj/10.2174/0102506882333546250115060157
/content/journals/nemj/10.2174/0102506882333546250115060157
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): HFpEF; Left heart disease; Phosphodiesterase type 5 inhibitors; Postcapillary PH; Pulmonary hypertension; Sildenafil

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test